Otros idiomas Johnson & Johnson Borsa Italiana

Acciones

4JNJ

US4781601046

Precio de cierre Borsa Italiana Otros sitios de cotización 00:00:00 31/05/2024			Varia. Cinco días.	Varia. 1 de enero.
135,3 ^EUR	+1,23 %		-1,15 %	-3,78 %

31/05	Actualización del sector: Los valores del sector sanitario suben a última hora de la tarde	MT
31/05	Los legisladores estadounidenses piden al FBI una sesión informativa sobre los vínculos de GenScript Biotech con China	RE

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Sector Update: Health Care Stocks Higher Late Afternoon	31/05
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	31/05
Sector Update: Health Care Stocks Advance Friday Afternoon	31/05
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars	31/05
Johnson & Johnson Closes Acquisition of Shockwave Medical	31/05
Johnson & Johnson completed the acquisition of Shockwave Medical, Inc. from a group of sellers.	31/05
Sarepta Therapeutics to Replace Shockwave Medical in S&P MidCap 400	30/05
Transcript : Johnson & Johnson Presents at Bernstein?s 40th Annual Strategic Decisions Conference, May-29-2024 01:30 PM	29/05
Johnson & Johnson's Phase 3 Trial of Seltorexant to Treat Major Depressive Disorder Meets Primary, Secondary Endpoints	29/05
J&J's treatment for depression succeeds in late stage study	29/05
Johnson & Johnson Announces Pivotal Study of Seltorexant Shows Statistically Significant and Clinically Meaningful Improvement in Depressive Symptoms and Sleep Disturbance Outcomes	29/05
Sector Update: Health Care Stocks Fall Late Afternoon	28/05
Sector Update: Health Care Stocks Retreat Tuesday Afternoon	28/05
Sector Update: Health Care	28/05
Bio-Thera, Stada Enter Deal for Biosimilar Candidate to Johnson & Johnson's Simponi in EU, UK	28/05
Johnson & Johnson Agrees to Buy Numab Unit, Investigational Skin Disease Treatment For $1.25 Billion	28/05
Top Midday Stories: Wall Street Returns to T+1 Settlements; T-Mobile Buys US Cellular's Wireless Ops; Energy Transfer Buys WTG Midstream; GameStop Extends Rally	28/05
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28/05
Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	28/05
J&J acquires rights to skin disorder drug for $1.25 bln	28/05

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Joseph Wolk, Director Financiero de J&J: Fin de la patente de su medicamento estrella

23 de enero 2024 a las 18:30